PMID- 15767827
OWN - NLM
STAT- MEDLINE
DCOM- 20050708
LR  - 20220317
IS  - 1075-2765 (Print)
IS  - 1075-2765 (Linking)
VI  - 12
IP  - 2
DP  - 2005 Mar-Apr
TI  - Safety, tolerability, and effectiveness of oxymorphone extended release for 
      moderate to severe osteoarthritis pain: a one-year study.
PG  - 106-12
AB  - A 52-week, multicenter, open-label extension study was performed to evaluate the 
      safety, tolerability, and effectiveness of oxymorphone extended release (ER), a 
      novel tablet formulation of oxymorphone hydrochloride, in 153 patients with 
      moderate to severe chronic osteoarthritis-related pain. Sixty-one patients 
      (39.9%) completed the study. Common opioid-related nonserious adverse events 
      (AEs) caused most withdrawals. However, approximately one-half of withdrawals due 
      to AEs were among opioid-naive patients who received placebo in a previous trial 
      and were started on a dose of 20 mg every 12 hours, suggesting that tolerability 
      can be improved by titrating from a lower initial dose. Mean pain scores 
      initially decreased as previously opioid-naive patients achieved adequate pain 
      relief, reached stable levels after the first 6 weeks, and remained stable at 
      mild levels throughout the remainder of the study (average pain, 20-25 mm on 
      100-mm Visual Analog Scale). Average daily dosing remained stable throughout the 
      study (median, 40 mg/d). At each assessment, at least 80% of patients rated their 
      global satisfaction with oxymorphone ER as "excellent," "very good," or "good." 
      Oxymorphone ER provides a new 12-hour analgesic for the treatment of moderate to 
      severe chronic osteoarthritis-related pain in patients who may require long-term 
      opioid therapy.
FAU - McIlwain, Harris
AU  - McIlwain H
AD  - Tampa Medical Group Research, 4700 N. Habana Avenue, Suite 303, Tampa, FL 33614, 
      USA. hmcil@aol.com
FAU - Ahdieh, Harry
AU  - Ahdieh H
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Ther
JT  - American journal of therapeutics
JID - 9441347
RN  - 0 (Analgesics, Opioid)
RN  - 0 (Delayed-Action Preparations)
RN  - 9VXA968E0C (Oxymorphone)
SB  - IM
MH  - Analgesics, Opioid/administration & dosage/adverse effects/*therapeutic use
MH  - Chronic Disease
MH  - Delayed-Action Preparations
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Osteoarthritis/*complications
MH  - Oxymorphone/administration & dosage/adverse effects/*therapeutic use
MH  - Pain/*drug therapy/etiology
MH  - Pain Measurement
EDAT- 2005/03/16 09:00
MHDA- 2005/07/09 09:00
CRDT- 2005/03/16 09:00
PHST- 2005/03/16 09:00 [pubmed]
PHST- 2005/07/09 09:00 [medline]
PHST- 2005/03/16 09:00 [entrez]
AID - 00045391-200503000-00002 [pii]
AID - 10.1097/01.mjt.0000139442.65914.f9 [doi]
PST - ppublish
SO  - Am J Ther. 2005 Mar-Apr;12(2):106-12. doi: 10.1097/01.mjt.0000139442.65914.f9.